-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Buy on Regenxbio, Lowers Price Target to $14

Benzinga·05/15/2026 17:55:10
Listen to the news
B of A Securities analyst Geoff Meacham maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $25 to $14.